Sivasubramanian S, Vijayshankar C S, Krishnamurthy S M, Santhosham R, Dwaraknath V, Rajaram S
Department of Cardiothoracic Surgery, Govt. General Hospital, Madras, India.
J Heart Valve Dis. 1996 Sep;5(5):548-52.
Thrombotic occlusion is a potentially fatal complication of heart valve replacement surgery. The purpose of this report is to present our experience in the treatment of this group of patients, with emphasis on valve debridement as an effective surgical cure.
Of 299 operative survivors undergoing valve replacement with Sorin Carbocast tilting disc prostheses at our institution 270 could be followed up: 18 of them (6.7%) developed thrombosis within 26 months. All thrombotic blocks occurred in the mitral position. Anticoagulation was sub-therapeutic in 13 patients. Clinically, the patients presented with dyspnea, congestive cardiac failure, acute pulmonary edema or chest pain. Prosthetic valve closure sounds were absent or muffled in all patients and new murmurs developed in two. The average duration of symptoms was 3.0 days (range eight hours to 15 days). Diagnosis was made on physical examination alone, and echocardiographic confirmation was possible in 11 patients. Ten underwent emergency surgery, all by valve debridement with retention of the prosthesis.
Of the operated patients, eight survived with restoration of prosthetic valve function. Complications including hypoxic encephalopathy and acute renal failure occurred in two patients (20%). One death occurred 13 months later due to renal failure. At a follow up of 18 to 32 months (mean 21.3 months), seven patients are alive and well, and in NYHA functional class I or II. One patient developed a recurrent prosthetic valve thrombotic occlusion, and underwent successful surgical debridement for a second time. Thrombolysis was attempted in two cases with early success, but recurrent prosthetic valve thrombosis occurred.
The incidence of PVT was 6.7% in 270 patients with Sorin tilting disc valves implanted and followed up for 26 months. Though thrombolysis is initially successful, recurrent valve thrombosis is a risk. Emergency surgical treatment allowed 70% mid term survival after valve debridement alone. Adequate anticoagulation and regular medical follow up postoperatively need to be strongly emphasized.
血栓形成性阻塞是心脏瓣膜置换手术一种潜在的致命并发症。本报告的目的是介绍我们治疗这类患者的经验,重点是瓣膜清创术作为一种有效的手术治疗方法。
在我们机构接受Sorin Carbocast倾斜碟片人工瓣膜置换手术的299例手术幸存者中,270例得到随访:其中18例(6.7%)在26个月内发生血栓形成。所有血栓块均发生在二尖瓣位置。13例患者抗凝治疗未达有效水平。临床上,患者表现为呼吸困难、充血性心力衰竭、急性肺水肿或胸痛。所有患者人工瓣膜关闭音消失或减弱,2例出现新的杂音。症状平均持续时间为3.0天(范围8小时至15天)。仅通过体格检查做出诊断,11例患者可行超声心动图确诊。10例患者接受急诊手术,均采用保留人工瓣膜的瓣膜清创术。
手术患者中,8例存活,人工瓣膜功能恢复。2例患者(20%)出现包括缺氧性脑病和急性肾衰竭在内的并发症。1例患者13个月后因肾衰竭死亡。在18至32个月(平均21.3个月)的随访中,7例患者存活且状况良好,纽约心脏协会(NYHA)心功能分级为I级或II级。1例患者人工瓣膜再次发生血栓形成性阻塞,并成功接受了第二次手术清创。2例尝试溶栓治疗且早期成功,但人工瓣膜再次发生血栓形成。
270例植入Sorin倾斜碟片瓣膜并随访26个月的患者中,人工瓣膜血栓形成(PVT)的发生率为6.7%。尽管溶栓治疗最初成功,但人工瓣膜再次发生血栓形成是一种风险。急诊手术治疗使仅行瓣膜清创术后的中期生存率达到70%。术后需强烈强调充分抗凝和定期医学随访。